142 related articles for article (PubMed ID: 35131084)
21. Dual targeting of EZH2 and androgen receptor as a novel therapy for castration-resistant prostate cancer.
Shankar E; Franco D; Iqbal O; Moreton S; Kanwal R; Gupta S
Toxicol Appl Pharmacol; 2020 Oct; 404():115200. PubMed ID: 32805266
[TBL] [Abstract][Full Text] [Related]
22. The functions of EZH2 in immune cells: Principles for novel immunotherapies.
Shao FF; Chen BJ; Wu GQ
J Leukoc Biol; 2021 Jul; 110(1):77-87. PubMed ID: 33040370
[TBL] [Abstract][Full Text] [Related]
23. NF-YA promotes invasion and angiogenesis by upregulating EZH2-STAT3 signaling in human melanoma cells.
Xu Z; Sun Y; Guo Y; Qin G; Mu S; Fan R; Wang B; Gao W; Wu H; Wang G; Zhang Z
Oncol Rep; 2016 Jun; 35(6):3630-8. PubMed ID: 27109360
[TBL] [Abstract][Full Text] [Related]
24. Genetic or pharmacologic blockade of enhancer of zeste homolog 2 inhibits the progression of peritoneal fibrosis.
Shi Y; Tao M; Wang Y; Zang X; Ma X; Qiu A; Zhuang S; Liu N
J Pathol; 2020 Jan; 250(1):79-94. PubMed ID: 31579944
[TBL] [Abstract][Full Text] [Related]
25. EZH2-CCF-cGAS Axis Promotes Breast Cancer Metastasis.
Duan D; Shang M; Han Y; Liu J; Liu J; Kong SH; Hou J; Huang B; Lu J; Zhang Y
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163710
[TBL] [Abstract][Full Text] [Related]
26. Mi-2β promotes immune evasion in melanoma by activating EZH2 methylation.
Li C; Wang Z; Yao L; Lin X; Jian Y; Li Y; Zhang J; Shao J; Tran PD; Hagman JR; Cao M; Cong Y; Li HY; Goding CR; Xu ZX; Liao X; Miao X; Cui R
Nat Commun; 2024 Mar; 15(1):2163. PubMed ID: 38461299
[TBL] [Abstract][Full Text] [Related]
27. Acid-Ionizable Iron Nanoadjuvant Augments STING Activation for Personalized Vaccination Immunotherapy of Cancer.
Chen F; Li T; Zhang H; Saeed M; Liu X; Huang L; Wang X; Gao J; Hou B; Lai Y; Ding C; Xu Z; Xie Z; Luo M; Yu H
Adv Mater; 2023 Mar; 35(10):e2209910. PubMed ID: 36576344
[TBL] [Abstract][Full Text] [Related]
28. The complex role of EZH2 in the tumor microenvironment: opportunities and challenges for immunotherapy combinations.
Qiu J; Sharma S; Rollins RA; Paul TA
Future Med Chem; 2020 Aug; 12(15):1415-1430. PubMed ID: 32723083
[TBL] [Abstract][Full Text] [Related]
29. EZH2-Targeted Therapies in Cancer: Hype or a Reality.
Eich ML; Athar M; Ferguson JE; Varambally S
Cancer Res; 2020 Dec; 80(24):5449-5458. PubMed ID: 32978169
[TBL] [Abstract][Full Text] [Related]
30. EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression.
Fan T; Jiang S; Chung N; Alikhan A; Ni C; Lee CC; Hornyak TJ
Mol Cancer Res; 2011 Apr; 9(4):418-29. PubMed ID: 21383005
[TBL] [Abstract][Full Text] [Related]
31. Enhancer of zeste homolog 2 promotes cisplatin resistance by reducing cellular platinum accumulation.
Sun S; Zhao S; Yang Q; Wang W; Cai E; Wen Y; Yu L; Wang Z; Cai J
Cancer Sci; 2018 Jun; 109(6):1853-1864. PubMed ID: 29630768
[TBL] [Abstract][Full Text] [Related]
32. Circular RNA circRNA_0082835 promotes progression and lymphatic metastasis of primary melanoma by sponging microRNA miRNA-429.
Sun Y; Hou Z; Luo B; Li C; Liu J; Liu J; Tang J; Yao G
Bioengineered; 2021 Dec; 12(1):4159-4173. PubMed ID: 34288815
[TBL] [Abstract][Full Text] [Related]
33. Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non-small cell lung cancer.
Shi B; Behrens C; Vaghani V; Riquelme EM; Rodriguez-Canales J; Kadara H; Lin H; Lee J; Liu H; Wistuba I; Simon G
Cancer Med; 2019 Oct; 8(14):6383-6392. PubMed ID: 31456359
[TBL] [Abstract][Full Text] [Related]
34. EZH2 is a negative prognostic biomarker associated with immunosuppression in hepatocellular carcinoma.
Guo B; Tan X; Cen H
PLoS One; 2020; 15(11):e0242191. PubMed ID: 33180829
[TBL] [Abstract][Full Text] [Related]
35. LSD1 collaborates with EZH2 to regulate expression of interferon-stimulated genes.
Jin Y; Huo B; Fu X; Hao T; Zhang Y; Guo Y; Hu X
Biomed Pharmacother; 2017 Apr; 88():728-737. PubMed ID: 28152483
[TBL] [Abstract][Full Text] [Related]
36. Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes.
Tiffen JC; Gunatilake D; Gallagher SJ; Gowrishankar K; Heinemann A; Cullinane C; Dutton-Regester K; Pupo GM; Strbenac D; Yang JY; Madore J; Mann GJ; Hayward NK; McArthur GA; Filipp FV; Hersey P
Oncotarget; 2015 Sep; 6(29):27023-36. PubMed ID: 26304929
[TBL] [Abstract][Full Text] [Related]
37. AP-2α-Mediated Activation of E2F and EZH2 Drives Melanoma Metastasis.
White JR; Thompson DT; Koch KE; Kiriazov BS; Beck AC; van der Heide DM; Grimm BG; Kulak MV; Weigel RJ
Cancer Res; 2021 Sep; 81(17):4455-4470. PubMed ID: 34210752
[TBL] [Abstract][Full Text] [Related]
38. EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma.
Julia E; Salles G
Future Oncol; 2021 Jun; 17(17):2127-2140. PubMed ID: 33709777
[TBL] [Abstract][Full Text] [Related]
39. Blockade of enhancer of zeste homolog 2 alleviates renal injury associated with hyperuricemia.
Shi Y; Xu L; Tao M; Fang L; Lu J; Gu H; Ma S; Lin T; Wang Y; Bao W; Qiu A; Zhuang S; Liu N
Am J Physiol Renal Physiol; 2019 Mar; 316(3):F488-F505. PubMed ID: 30566000
[TBL] [Abstract][Full Text] [Related]
40. EZH2 upregulation by ERα induces proliferation and migration of papillary thyroid carcinoma.
Xue L; Yan H; Chen Y; Zhang Q; Xie X; Ding X; Wang X; Qian Z; Xiao F; Song Z; Wu Y; Peng Y; Xu H
BMC Cancer; 2019 Nov; 19(1):1094. PubMed ID: 31718595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
